AEMD
AETHLON MEDICAL INC
$2.03
+6.28%
$4.5M
No data for this timeframe.
Vol
Market Cap$4.5M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$5.7K
SEC Reports1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. NV·CIK 0000882291·Prev Close $1.91
Recent Activity
Jun 4, 2026
SEC
Aethlon Medical filed an 8-K and a 424B5 prospectus supplement to update the amount of common stock it may sell under it
8-K, 424B5 — Impact 5/10
Apr 17, 2026
Insider
Gikakis Nicolas sold 21,815 shares
Director @ $2.29 ($50.0K)
Apr 17, 2026
Insider
Shah Chetan sold 21,815 shares
Director @ $2.29 ($50.0K)
Apr 17, 2026
Insider
Rossetti Angela sold 21,815 shares
Director @ $2.29 ($50.0K)
Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$4.75 (Aug 2025)
Current $1.94
Low $1.50
Median $4.75
High $8.00
2 analysts
$1.50
$8.00
Analyst Ratings
0Strong Buy
0Buy
4Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 14, 2025 | HC Wainwright & Co. | REITERATE | Neutral → Neutral |
| Mar 10, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 19, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 30, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 15, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.46 | $-2.47 — $-2.44 | 93% YoY | 2 |
| Next Q | $-0.23 ▲ +83.6% | $-0.23 — $-0.23 | 97% YoY | 1 |
| Current FY | $-10.40 | $-10.40 — $-10.40 | 88% YoY | 1 |
| Next FY | $-0.98 ▲ +82.8% | $-0.98 — $-0.98 | 91% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $5.7K | — |
| BANK OF AMERICA CORP | $17.00 | — |
| WELLS FARGO & COMPANY/MN | $7.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 17, 2026 | Gikakis Nicolas | A | $50.0K |
| Apr 17, 2026 | Shah Chetan | A | $50.0K |
| Apr 17, 2026 | Rossetti Angela | A | $50.0K |
| Apr 17, 2026 | BROENNIMAN EDWARD | A | $50.0K |
| Mar 31, 2026 | BROENNIMAN EDWARD | F | $194.91 |
3 institutional holders with $5.7K total value (2,056 shares) as of 2025-Q4. Top holders: MORGAN, BANK, WELLS.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 2,047 | $5.7K | 99.6% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 6 | $17.00 | 0.3% | — |
| 3 | WELLS FARGO & COMPANY/MN | 3 | $7.00 | 0.1% | — |
4 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 17, 2026 | Gikakis Nicolas | Director | A | 21,815 | $2.29 | $50.0K |
| Apr 17, 2026 | Shah Chetan | Director | A | 21,815 | $2.29 | $50.0K |
| Apr 17, 2026 | Rossetti Angela | Director | A | 21,815 | $2.29 | $50.0K |
| Apr 17, 2026 | BROENNIMAN EDWARD G | Director | A | 21,815 | $2.29 | $50.0K |
| Mar 31, 2026 | BROENNIMAN EDWARD G | Director | F | 89 | $2.19 | $194.91 |
| Mar 31, 2026 | Shah Chetan | Director | F | 178 | $2.19 | $389.82 |
| Mar 31, 2026 | Gikakis Nicolas | Director | F | 178 | $2.19 | $389.82 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Aug 2025): 0% buy across 7 analysts — 0 strong buy, 0 buy, 4 hold, 1 sell, 2 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$4.75 mean target (Aug 2025)
$1.50 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $1.94 |
| Target Low | $1.50 |
| Target Mean | $4.75 |
| Target Median | $4.75 |
| Target High | $8.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-2.46 | $-2.47 | $-2.44 | 93.4% | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-06-30 |
$-0.23 | $-0.23 | $-0.23 | 97.3% | +83.6% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-03-31 |
$-10.40 | $-10.40 | $-10.40 | 87.9% | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-03-31 |
$-0.98 | $-0.98 | $-0.98 | 90.6% | +82.8% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.455 | |
| 7d ago | $-2.455 | |
| 30d ago | $-2.455 | |
| 60d ago | $-2.020 | -0.435 |
| 90d ago | $-2.020 | -0.435 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 14, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Mar 10, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 19, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 30, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 24, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 4, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Oct 24, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.